2003PubMedRequires access

[A study of protein kinase C signal pathway in regulating airway smooth muscle cell proliferation in asthmatic rats].

Shuyun Xu, Yongjian Xu, Zhenxiang Zhang, Ni Wang, Shixin Chen

Open publisher page 4 citations

Abstract

OBJECTIVE: To investigate the role of protein kinase C (PKC) signal pathway in airway smooth muscle cell (ASMCs) proliferation in asthmatic rats. METHODS: (1) Forty-eight Wistar rats were divided into an asthmatic group (group A) and a control group (group B), and then subdivided into group A(1), A(2), A(3) and group B(1), B(2), B(3) based on the time of challenge (2, 4, 8 weeks). The proliferation of ASMCs isolated from group A and B was examined with cell cycle analysis, MTT colorimetric assay and proliferating cell nuclear antigen (PCNA) immunocytochemical staining. (2) ASMCs from group A(1) and B(1) were treated with PKC agonist PMA and inhibitor Ro-31-8220, and their proliferations were examined. (3) The expression of PKC-alpha in group A(1), A(2), A(3) and B(1) was observed by immunocytochemical staining and RT-PCR, respectively. RESULTS: (1) The percentage of S phase, absorbance (A) value and the expression rate of PCNA protein in ASMCs from group A were significantly increased compared to those of group B (P < 0.01). (2) Before ASMCs from A(1) group were treated, the percentage of S phase, A value and the expression rate of PCNA were (19 +/- 3)%, 0.459 +/- 0.036, and (80 +/- 10)% respectively; After treated with 10 nmol/L PMA, these values reached (27 +/- 4)%, 0.599 +/- 0.078, and (95 +/- 9)% respectively; After treated with 50 nmol/L PMA, these values were (14 +/- 3)%, 0.346 +/- 0.038, and (53 +/- 8)% respectively; After treatment with Ro-31-8220, these values were (14 +/- 3)%, 0.343 +/- 0.048, and (49 +/- 8)% respectively. Statistical analysis revealed that there were significant differences in the percentage of S phase, A value and the expression of PCNA before and after treatment (P < 0.01). After treatment with 50 nmol/L PMA, there was a significant difference as compared to 10 nmol/L PMA treatment (P < 0.01), whereas there was no statistical significance as compared to Ro-31-8220 treatment (P > 0.05). (3) Compared with that of group B(1) (0.84 +/- 0.07), the ratios of A value of PKC-alpha mRNA in group A(1) (1.08 +/- 0.06), group A(2) (1.12 +/- 0.05), and group A(3) (1.10 +/- 0.08) were significantly increased (P < 0.01). Compared with that of group B(1) (28 +/- 4)%, the expression rates of PKC-alpha protein in group A(1) (54 +/- 5)%, group A(2) (56 +/- 5)%, and group A(3) (53 +/- 6)% were significantly increased (P < 0.01). CONCLUSIONS: Airway smooth muscle cell proliferation increases in asthmatic rats. PKC and it's alpha subtype may contribute to this process.

About this research paper

What this paper is about

OBJECTIVE: To investigate the role of protein kinase C (PKC) signal pathway in airway smooth muscle cell (ASMCs) proliferation in asthmatic rats. METHODS: (1) Forty-eight Wistar rats were divided into an asthmatic group (group A) and a control group (group B), and then subdivided into group A(1), A(2), A(3) and group B(1), B(2), B(3) based on the time of challenge (2, 4, 8 weeks). The proliferation of ASMCs isolated from group A and B was examined with cell cycle analysis, MTT colorimetric assay and proliferating cell nuclear antigen (PCNA) immunocytochemical staining. (2) ASMCs from group A(1) and B(1) were treated with PKC agonist PMA and inhibitor Ro-31-8220, and their proliferations were examined. (3) The expression of PKC-alpha in group A(1), A(2), A(3) and B(1) was observed by immunocytochemical staining and RT-PCR, respectively. RESULTS: (1) The percentage of S phase, absorbance (A) value and the expression rate of PCNA protein in ASMCs from group A were significantly increased compared to those of group B (P < 0.01). (2) Before ASMCs from A(1) group were treated, the percentage of S phase, A value and the expression rate of PCNA were (19 +/- 3)%, 0.459 +/- 0.036, and (80 +/- 10)% respectively; After treated with 10 nmol/L PMA, these values reached (27 +/- 4)%, 0.599 +/- 0.078, and (95 +/- 9)% respectively; After treated with 50 nmol/L PMA, these values were (14 +/- 3)%, 0.346 +/- 0.038, and (53 +/- 8)% respectively; After treatment with Ro-31-8220, these values were (14 +/- 3)%, 0.343 +/- 0.048, and (49 +/- 8)% respectively. Statistical analysis revealed that there were significant differences in the percentage of S phase, A value and the expression of PCNA before and after treatment (P < 0.01). After treatment with 50 nmol/L PMA, there was a significant difference as compared to 10 nmol/L PMA treatment (P < 0.01), whereas there was no statistical significance as compared to Ro-31-8220 treatment (P > 0.05). (3) Compared with that of group B(1) (0.84 +/- 0.07), the ratios of A value of PKC-alpha mRNA in group A(1) (1.08 +/- 0.06), group A(2) (1.12 +/- 0.05), and group A(3) (1.10 +/- 0.08) were significantly increased (P < 0.01). Compared with that of group B(1) (28 +/- 4)%, the expression rates of PKC-alpha protein in group A(1) (54 +/- 5)%, group A(2) (56 +/- 5)%, and group A(3) (53 +/- 6)% were significantly increased (P < 0.01). CONCLUSIONS: Airway smooth muscle cell proliferation increases in asthmatic rats. PKC and it's alpha subtype may contribute to this process.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: To investigate the role of protein kinase C (PKC) signal pathway in airway smooth muscle cell (ASMCs) proliferation in asthmatic rats. METHODS: (1) Forty-eight Wistar rats were divided into an asthmatic group (group A) and a control group (group B), and then subdivided into group A(1), A(2), A(3) and group B(1), B(2), B(3) based on the time of challenge (2, 4, 8 weeks). The proliferation of ASMCs isolated from group A and B was examined with cell cycle analysis, MTT colorimetric assay and proliferating cell nuclear antigen (PCNA) immunocytochemical staining. (2) ASMCs from group A(1) and B(1) were treated with PKC agonist PMA and inhibitor Ro-31-8220, and their proliferations were examined. (3) The expression of PKC-alpha in group A(1), A(2), A(3) and B(1) was observed by immunocytochemical staining and RT-PCR, respectively. RESULTS: (1) The percentage of S phase, absorbance (A) value and the expression rate of PCNA protein in ASMCs from group A were significantly increased compared to those of group B (P < 0.01). (2) Before ASMCs from A(1) group were treated, the percentage of S phase, A value and the expression rate of PCNA were (19 +/- 3)%, 0.459 +/- 0.036, and (80 +/- 10)% respectively; After treated with 10 nmol/L PMA, these values reached (27 +/- 4)%, 0.599 +/- 0.078, and (95 +/- 9)% respectively; After treated with 50 nmol/L PMA, these values were (14 +/- 3)%, 0.346 +/- 0.038, and (53 +/- 8)% respectively; After treatment with Ro-31-8220, these values were (14 +/- 3)%, 0.343 +/- 0.048, and (49 +/- 8)% respectively. Statistical analysis revealed that there were significant differences in the percentage of S phase, A value and the expression of PCNA before and after treatment (P < 0.01). After treatment with 50 nmol/L PMA, there was a significant difference as compared to 10 nmol/L PMA treatment (P < 0.01), whereas there was no statistical significance as compared to Ro-31-8220 treatment (P > 0.05). (3) Compared with that of group B(1) (0.84 +/- 0.07), the ratios of A value of PKC-alpha mRNA in group A(1) (1.08 +/- 0.06), group A(2) (1.12 +/- 0.05), and group A(3) (1.10 +/- 0.08) were significantly increased (P < 0.01). Compared with that of group B(1) (28 +/- 4)%, the expression rates of PKC-alpha protein in group A(1) (54 +/- 5)%, group A(2) (56 +/- 5)%, and group A(3) (53 +/- 6)% were significantly increased (P < 0.01). CONCLUSIONS: Airway smooth muscle cell proliferation increases in asthmatic rats. PKC and it's alpha subtype may contribute to this process.

Key concepts: Proliferating cell nuclear antigen, Protein kinase C, Cell growth, Molecular biology, Kinase, Endocrinology, Staining, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
[A study of protein kinase C signal pathway in regulating airway smooth muscle cell proliferation in asthmatic rats]. — Research Paper | ScholarLens